Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8257203 | 1.00 | HSD11B1 (0.53) | HSD11B1CYP2D6NPY5RAVPR1ASIGMAR1 | |
| SCHEMBL4887590 | 1.00 | HSD11B1 (0.53) | HSD11B1CYP2D6NPY5RAVPR1ASIGMAR1 | |
| SCHEMBL4882812 | 0.80 | HRH3 (0.48) | HSD11B1CYP2D6NPY5RAVPR1AHRH3 | |
| SCHEMBL4882807 | 0.80 | HRH3 (0.48) | HSD11B1CYP2D6NPY5RAVPR1AHRH3 | |
| SCHEMBL8260249 | 0.80 | HRH3 (0.48) | HSD11B1CYP2D6NPY5RAVPR1AHRH3 | |
| SCHEMBL11839484 | 0.75 | HRH3 (0.58) | HSD11B1CYP2D6NPY5RSIGMAR1HRH3 | |
| SCHEMBL4885388 | 0.75 | NPY5R (0.58) | HSD11B1CYP2D6NPY5RAVPR1ASIGMAR1 | |
| SCHEMBL8259094 | 0.75 | HSD11B1 (0.50) | HSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL4681026 | 0.75 | HSD11B1 (0.50) | HSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL4681025 | 0.75 | HSD11B1 (0.50) | HSD11B1CYP2D6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | HSD11B1 382/4885CYP2D6 325/4885NPY5R 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.